SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
Markus Hoffmann1, Hannah Kleine-Weber1,2, Simon Schroeder3,4, Nadine Krüger5,6, Tanja Herrler7, Sandra Erichsen8,9, Tobias S. Schiergens10, Georg Herrler5, Nai-Huei Wu5, Andreas Nitsche11, Marcel A. Müller3,4,12, Christian Drosten3,4, Stefan Pöhlmann1,2
1Infection Biology Unit, German Primate Center – Leibniz Institute for Primate Research, Göttingen, Germany
2Faculty of Biology and Psychology, University Göttingen, Göttingen, Germany
3Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Virology, Berlin, Germany
4German Centre for Infection Research, associated partner Charité, Berlin, Germany
5Institute of Virology, University of Veterinary Medicine Hannover, Hannover, Germany
6Research Center for Emerging Infections and Zoonoses, University of Veterinary Medicine Hannover, Hannover, Germany
7BG Unfallklinik Murnau, Murnau, Germany
8Institute for Biomechanics, BG Unfallklinik Murnau, Murnau, Germany
9Institute for Biomechanics, Paracelsus Medical University Salzburg, Salzburg, Austria
10Biobank of the Department of General, Visceral, and Transplant Surgery, Ludwig-Maximilians-University Munich, Munich, Germany
11Robert Koch Institute, ZBS 1 Highly Pathogenic Viruses, WHO Collaborating Centre for Emerging Infections and Biological Threats, Berlin, Germany
12Martsinovsky Institute of Medical Parasitology, Tropical and Vector Borne Diseases, Sechenov University, Moscow, Russia